As urged by the AHA, the Health Resources and Services Administration today announced that it expects to publish online by April 1 drug ceiling prices under the 340B Drug Pricing Program. HRSA also notified stakeholders that the secure pricing component of the 340B Office of Pharmacy Affairs Information System will be open for the submission of manufacturer pricing data in the first quarter of 2019.

The Department of Health and Human Services yesterday issued a final rule making Jan. 1 the effective date of its final regulations on drug ceiling prices and civil monetary penalties for manufacturers under the 340B program. The AHA said it was pleased that, in response to its lawsuit, the “final rule ensures that the implementation of the long-delayed” 340B ceiling price and civil monetary penalties policies will be effective Jan. 1. 

The AHA, Association of American Medical Colleges, America's Essential Hospitals, 340B Health and three hospital systems in September filed a lawsuit to force implementation of this rule in order to “shine needed light on drug pricing and to hold price-gouging drug companies accountable.”
 

Related News Articles

Headline
The Trump administration announced a trade agreement with the U.K. Dec. 1 on pharmaceuticals that exempts U.K. drug products from Section 232 tariffs. In…
Headline
The AHA, the Maine Hospital Association and four safety-net health systems from across the country Dec. 1 filed a lawsuit in the U.S. District…
Headline
The Centers for Medicare & Medicaid Services Nov. 25 announced lower prices for 15 Medicare Part D drugs selected for the second cycle of negotiations…
Chairperson's File
Public
For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription…
Chairperson's File
Public
In last month’s Chair File, we talked about some of the key priorities the AHA has for the remainder of 2025, one of which is protecting the 340B Drug Pricing…
Headline
The White House announced today that it reached agreements with Eli Lilly and Novo Nordisk to align their drug prices with the lowest paid by other developed…